Vir Biotechnology (NASDAQ:VIR) versus Bavarian Nordic A/S (OTCMKTS:BVNRY) Head to Head Analysis

Vir Biotechnology (NASDAQ:VIR) and Bavarian Nordic A/S (OTCMKTS:BVNRY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Vir Biotechnology and Bavarian Nordic A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0	1	5	0	2.83
Bavarian Nordic A/S	0	0	0	0	0.00

Vir Biotechnology currently has a consensus target price of $34.83, suggesting a potential upside of 227.69%. Given Vir Biotechnology’s stronger consensus rating and higher possible upside, equities analysts clearly believe Vir Biotechnology is more favorable than Bavarian Nordic A/S.

Profitability

This table compares Vir Biotechnology and Bavarian Nordic A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-678.40%	-36.71%	-31.00%
Bavarian Nordic A/S	18.33%	10.65%	7.90%

Volatility and Risk

Vir Biotechnology has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Bavarian Nordic A/S has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vir Biotechnology and Bavarian Nordic A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$86.18 million	16.99	-$615.06 million	($3.92)	-2.71
Bavarian Nordic A/S	$1.02 billion	2.14	$214.20 million	$0.69	13.44

Bavarian Nordic A/S has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Bavarian Nordic A/S, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.3% of Vir Biotechnology shares are owned by institutional investors. 15.6% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Bavarian Nordic A/S beats Vir Biotechnology on 8 of the 14 factors compared between the two stocks.

About Vir Biotechnology

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.